(0.30%) 5 115.25 points
(0.31%) 38 356 points
(0.31%) 15 977 points
(-0.93%) $83.07
(5.56%) $2.03
(0.36%) $2 355.70
(0.44%) $27.66
(4.05%) $959.40
(-0.24%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
本日の出来高 | 9 014.00 |
平均出来高 | 12 441.00 |
時価総額 | 32.86M |
EPS | $-0.000220 ( 2023-06-29 ) |
Last Dividend | $0.195 ( 2023-12-14 ) |
Next Dividend | $0 ( N/A ) |
P/E | -17.20 |
ATR14 | $0.254 (1.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Klein Dov | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 51 transactions |
Buy: 13 110 352 | Sell: 133 334 |
Fortress Biotech Inc. 相関
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Fortress Biotech Inc. 財務諸表
Annual | 2023 |
収益: | $84.51M |
総利益: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
収益: | $84.51M |
総利益: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
収益: | $75.74M |
総利益: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
収益: | $68.79M |
総利益: | $36.71M (53.36 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Fortress Biotech Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.390 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.586 | 2018-03-14 |
Last Dividend | $0.195 | 2023-12-14 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-31 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $13.86 | -- |
Avg. Dividend % Per Year | 7.56% | -- |
Score | 5.87 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 1.121 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $2.34 | 10.60% |
2019 | $2.34 | 14.50% |
2020 | $2.34 | 11.40% |
2021 | $2.34 | 12.10% |
2022 | $2.15 | 8.20% |
2023 | $2.34 | 13.30% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.724 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.365 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.56 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.143 | -1.000 | -1.432 | 1.432 | [0 - 1] |
currentRatioTTM | 1.378 | 0.800 | 8.11 | 6.49 | [1 - 3] |
quickRatioTTM | 1.134 | 0.800 | 8.03 | 6.43 | [0.8 - 2.5] |
cashRatioTTM | 0.953 | 1.500 | 5.82 | 8.72 | [0.2 - 2] |
debtRatioTTM | 0.420 | -1.500 | 3.01 | -4.51 | [0 - 0.6] |
interestCoverageTTM | -11.92 | 1.000 | -5.53 | -5.53 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -4.28 | -8.57 | [0 - 20] |
debtEquityRatioTTM | 3.12 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.680 | 1.000 | 1.999 | 1.999 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.681 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.824 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.504 | 0.800 | 9.97 | 7.98 | [0.5 - 2] |
Total Score | -2.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.424 | 1.000 | -0.144 | 0 | [1 - 100] |
returnOnEquityTTM | -2.56 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -2.86 | -8.57 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
payoutRatioTTM | -0.143 | 1.500 | -1.432 | 1.432 | [0 - 1] |
pegRatioTTM | -0.00785 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.517 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.87 |
Fortress Biotech Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。